

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/126731 A1

(51) International Patent Classification:

C07D 217/04 (2006.01) *C07D 487/04* (2006.01)
C07D 401/14 (2006.01) *A61K 31/519* (2006.01)
A61K 31/44 (2006.01) *A61K 31/4725* (2006.01)
C07D 471/04 (2006.01) *A61K 31/437* (2006.01)

(21) International Application Number:

PCT/US2020/064765

(22) International Filing Date:

14 December 2020 (14.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/949,248 17 December 2019 (17.12.2019) US
62/949,242 17 December 2019 (17.12.2019) US
63/025,629 15 May 2020 (15.05.2020) US

(71) Applicant: **MERCK SHARP & DOHME CORP.**

[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).

(72) Inventors; and

(71) Applicants (for US only): **MACHACEK, Michelle**
[US/US]; 33 Avenue Louis Pasteur, Boston, Massachu-
setts 02115-5727 (US). **ALTMAN, Michael, D.**
[US/US]; 33 Avenue Louis Pasteur, Boston, Massachu-
setts 02115-5727 (US). **HUANG, Chunhui** [CN/US]; 33
Avenue Louis Pasteur, Boston, Massachusetts 02115-5727
(US). **REUTERSHAN, Michael, H.** [US/US]; 33 Avenue
Louis Pasteur, Boston, Massachusetts 02115-5727 (US).
SLOMAN, David, L. [US/US]; 33 Avenue Louis Pas-





teur, Boston, Massachusetts 02115-5727 (US). **WITTER,
David, J.** [US/CA]; 6 Granite Court, Toronto, Ontario M8V
4A4 (CA). **GIBEAU, Craig, R.** [US/US]; 80 Little Pond
Road, Northborough, Massachusetts 01532 (US).

(74) Common Representative: **MERCK SHARP & DOHME
CORP.**; 126 East Lincoln Avenue, Rahway, New Jersey
07065-0907 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: PRMT5 INHIBITORS



(57) Abstract: The present invention provides a compound selected from: compounds A, B, C, D and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutical compositions comprising compounds disclosed herein, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*